11 news items
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
MNKD
29 May 24
, depending on the target indication. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
MNKD
PULM
29 May 24
," "guides," "intends," "is confident that", "may," "plans," "seeks," "projects," "targets
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $6.5 Price Target
MNKD
9 May 24
Cantor Fitzgerald analyst Olivia Brayer reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $6.5 price target.
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
MNKD
8 May 24
locally or enter the systemic circulation, depending on the target indication. With a passionate team of Mannitarians collaborating
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
MNKD
6 May 24
on the target indication. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health
nyjtnoooccd4ua6rstdx2p3h36x
MNKD
30 Apr 24
exert an effect locally or enter the systemic circulation, depending on the target indication. With a passionate team of Mannitarians
s62f5zkonc91ef4ndf7803lqevcc3iz5uy5mfmy3tq hd56t2
MNKD
29 Apr 24
an effect locally or enter the systemic circulation, depending on the target indication. With a passionate team of Mannitarians collaborating
rapnt6c ax18l40uo8thk9byy92n74rd4
MNKD
15 Mar 24
Cantor Fitzgerald analyst Olivia Brayer reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $6.5 price target.
77s1u0uelxyx7s0493
ATXI
BALY
BIAF
11 Mar 24
price target from $10 to $11. The stock is also gaining amid overall China strength following the annual National People's Congress event
tov4vv3u0sb7kcx0z1s4lrx6yp0 pbpsn06z4vonmxoqyhw2biuy0sclrh
APLT
ARQT
ARWR
11 Mar 24
. Cormark Securities analyst Jesse Pytlak initiated coverage on Celestica with a Buy rating and announced a price target of $56
qefbyg2wvqxm424fpnk6948yp4uli 7vb73yn88yxww8
MNKD
11 Mar 24
higher from current levels, it's a good idea to take a look at analyst forecasts.
Wall Street analysts have an average 12-month price target
- Prev
- 1
- Next